Topical ganciclovir in the treatment of acute herpetic keratitis
暂无分享,去创建一个
[1] A. Nikkels,et al. Severe herpes simplex virus type-I infections after dental procedures. , 2011, Medicina oral, patologia oral y cirugia bucal.
[2] S. Chee,et al. Cytomegalovirus anterior uveitis: outcome of treatment , 2010, British Journal of Ophthalmology.
[3] R. H. Bonneau,et al. Stress-Induced Glucocorticoids at the Earliest Stages of Herpes Simplex Virus-1 Infection Suppress Subsequent Antiviral Immunity, Implicating Impaired Dendritic Cell Function , 2010, The Journal of Immunology.
[4] K. Tabbara. Pharmacologic strategies in the prevention and treatment of corneal transplant rejection , 2008, International Ophthalmology.
[5] J. Colin. Ganciclovir ophthalmic gel, 0.15%: a valuable tool for treating ocular herpes , 2007, Clinical ophthalmology.
[6] K. Wilhelmus. Therapeutic interventions for herpes simplex virus epithelial keratitis. , 2007, The Cochrane database of systematic reviews.
[7] S. Kaye,et al. Herpes simplex keratitis , 2006, Progress in Retinal and Eye Research.
[8] S. Majumdar,et al. Dipeptide monoester ganciclovir prodrugs for treating HSV-1-induced corneal epithelial and stromal keratitis: in vitro and in vivo evaluations. , 2005, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.
[9] K. Tabbara. Treatment of herpetic keratitis. , 2005, Ophthalmology.
[10] E. Miserocchi,et al. Comparison of the Efficacy of Valacyclovir vs Acyclovir for the Prevention of Recurrent Herpes Simplex Virus Eye Disease , 2005 .
[11] M. Labetoulle. Actualités thérapeutiques de l’herpès cornéen , 2004 .
[12] M. Labetoulle. [The latest in herpes simplex keratitis therapy]. , 2004, Journal francais d'ophtalmologie.
[13] C. Begley,et al. Prevention of herpes simplex virus eye disease: a cost-effectiveness analysis. , 2003, Archives of ophthalmology.
[14] G. Cockerham. Primary graft failure caused by herpes simplex virus type 1. , 2001, Cornea.
[15] P. Watts,et al. Ganciclovir and Penciclovir, but Not Acyclovir, Induce Apoptosis in Herpes Simplex Virus Thymidine Kinasetransformed Baby Hamster Kidney Cells , 2001, Antiviral chemistry & chemotherapy.
[16] T. Zeyen,et al. Primary Graft Failure Caused by Herpes Simplex Virus Type 1 , 2001, Cornea.
[17] K. Wilhelmus. The treatment of herpes simplex virus epithelial keratitis. , 2000, Transactions of the American Ophthalmological Society.
[18] E. Donnenfeld. Oral acyclovir for herpes simplex virus eye disease: effect on prevention of epithelial keratitis and stromal keratitis. Herpetic Eye Disease Study Group. , 2000, Archives of ophthalmology.
[19] Y. Akova,et al. Efficacy of low-dose and long-term oral acyclovir therapy after penetrating keratoplasty for herpes simplex heratitis. , 1999, Ocular immunology and inflammation.
[20] S. Resnikoff,et al. Ganciclovir ophthalmic gel (Virgan; 0.15%) in the treatment of herpes simplex keratitis. , 1997, Cornea.
[21] D. Easty,et al. Randomised trial of ganciclovir and acyclovir in the treatment of herpes simplex dendritic keratitis: a multicentre study. , 1996, The British journal of ophthalmology.
[22] L. J. Nelson,et al. Herpetic Eye Disease Study. A controlled trial of oral acyclovir for herpes simplex stromal keratitis. , 1994, Ophthalmology.
[23] C. Crumpacker,et al. Recurrence and Resistance Patterns of Herpes Simplex Virus following Cessation of ⩾6 Years of Chronic Suppression with Acyclovir , 1994 .
[24] P. Goldschmidt,et al. Ganciclovir ophthalmic gel in herpes simplex virus rabbit keratitis: intraocular penetration and efficacy. , 1994, Journal of ocular pharmacology.
[25] L. Goldberg,et al. Continuous five‐year treatment of patients with frequently recurring genital herpes simplex virus infection with acyclovir , 1993, Journal of medical virology.
[26] R. Frothingham,et al. Acyclovir-resistant herpes simplex virus keratouveitis after penetrating keratoplasty. , 1992, Ophthalmology.
[27] D. H. Watts,et al. Antiviral agents. , 1992, Obstetrics and gynecology clinics of North America.
[28] E. Cohen,et al. Indications for and outcomes of repeat penetrating keratoplasty. , 1990, American journal of ophthalmology.
[29] L. Ficker,et al. The changing management and improved prognosis for corneal grafting in herpes simplex keratitis. , 1989, Ophthalmology.
[30] J. Mills,et al. Prolonged continuous versus intermittent oral acyclovir treatment in normal adults with frequently recurring genital herpes simplex virus infection. , 1988, The American journal of medicine.
[31] R. D. Stulting,et al. Penetrating keratoplasty for herpes simplex keratitis and keratoconus. Allograft rejection and survival. , 1987, Ophthalmology.
[32] M. Davies,et al. 2'-Nor-2'-deoxyguanosine is an effective therapeutic agent for treatment of experimental herpes keratitis. , 1987, Antiviral research.
[33] H. Shiota,et al. Anti-herpes simplex virus (HSV) effect of 9-(1,3-dihydroxy-2-propoxymethyl)guanine (DHPG) in rabbit cornea. , 1987, Current eye research.
[34] E. Romanowski,et al. 2'-nor-cGMP, a new cyclic derivative of 2'NDG, inhibits HSV-1 replication in vitro and in the mouse keratitis model. , 1987, Current eye research.
[35] H. E. Kaufman,et al. Herpes simplex keratitis. , 1983, Ophthalmology.